Bikbov, Mukharram M.
Kazakbaeva, Gyulli M.
Panda-Jonas, Songhomitra
Khakimov, Dinar A.
Gilemzianova, Leisan I.
Miniazeva, Liana A.
Tuliakova, Azaliia M.
Fakhretdinova, Albina A.
Kazakbaev, Renat A.
Nuriev, Ildar F.
Jonas, Jost B.
Funding for this research was provided by:
Medizinische Fakultät Mannheim der Universität Heidelberg
Article History
Received: 25 February 2022
Accepted: 27 June 2022
First Online: 6 July 2022
Competing interests
: Jost B. Jonas, Songhomitra Panda-Jonas: European patent EP 3 271 392, JP 2021-119187, and US 2021 0340237 A1: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Patent application: European patent application: WO 2021/198369 A1; PCT/EP2021/058500: Agents for the use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases. All other authors: None.